There is an extreme necessity for the utilization of accessible and reliable, low-cost biomarkers to avoid unnecessary routine use of colonoscopy in diagnosing IBS in low-risk population with age <50 years, no history of GIT bleeding, nocturnal passage of stool, weight loss, familial history of inflammatory bowel diseases or colorectal cancer, recent bowel habits changes, and/or the presence of abdominal masses or lymaphadenopathy.1,20 Previous studies reported that anti-CdtB and anti-vinculin might be valuable noninvasive biomarkers to identify IBS patients21,22 in different populations. Here, VCL is linked to inflammatory bowel disease.